BRUSSELS (Reuters) - EU antitrust regulators will decide by Nov. 9 whether to clear U.S. pharmaceuticals company Abbott Laboratories' <ABT.N> $25-billion bid for St. Jude Medical Inc <STJ.N> aimed at helping it better compete with bigger rivals.
Abbott sought the European Commission's approval for the deal on Oct. 3, according to a filing on the EU competition enforcer's website on Tuesday.
The Commission can either clear the deal with or without concessions or it can open a full-scale investigation if it has serious concerns. The majority of pharmaceutical mergers get the green light with or without conditions in the EU's preliminary review.
- There's fanfic at The Met and it's all because of the Tale of Genji21 Pictures
- Oscars 2019: Red carpet looks and full list of winners36 Pictures
Abbott's takeover bid comes as medical equipment makers come under pressure to offer a wider portfolio of products to hospital customers, which have gained more negotiating power on pricing after a wave of mergers.
Abbott competes against Medtronic Plc <MDT.N> and Boston Scientific Corp <BSX.N>.
(Reporting by Foo Yun Chee; Editing by Mark Potter)